Terms: = Kidney tumors AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
95 results:
1. Diagnosis and treatment of bilateral adrenal pheochromocytoma with ret gene mutation combined with medullary sponge kidney: A case report.
Shen P; Yin N; Sun L; Liu Y; Cao X
Medicine (Baltimore); 2023 Jun; 102(23):e34022. PubMed ID: 37335636
[TBL] [Abstract] [Full Text] [Related]
2. ret signaling in breast cancer therapeutic resistance and metastasis.
Pecar G; Liu S; Hooda J; Atkinson JM; Oesterreich S; Lee AV
Breast Cancer Res; 2023 Mar; 25(1):26. PubMed ID: 36918928
[TBL] [Abstract] [Full Text] [Related]
3. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
Jin J; Xie Y; Zhang JS; Wang JQ; Dai SJ; He WF; Li SY; Ashby CR; Chen ZS; He Q
Drug Resist Updat; 2023 Mar; 67():100929. PubMed ID: 36739809
[TBL] [Abstract] [Full Text] [Related]
4. Rare duplication of the CDC73 gene and atypical hyperparathyroidism-jaw tumor syndrome: A case report and review of the literature.
Garrigues G; Batisse-Lignier M; Uhrhammer N; Privat M; Ponelle-Chachuat F; Kelly A; Gay-Bellile M; Viala S; Bidet Y; Bignon YJ; Cavaillé M
Mol Genet Genomic Med; 2023 May; 11(5):e2133. PubMed ID: 36639964
[TBL] [Abstract] [Full Text] [Related]
5. Recurrent ret fusions in fibrosarcoma-like neoplasms in adult viscera: expanding the clinicopathological and genetic spectrum.
Zhao M; Yin X; He H; Xia Q; Ru G
Histopathology; 2023 Mar; 82(4):633-645. PubMed ID: 36443894
[TBL] [Abstract] [Full Text] [Related]
6. Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms' tumor.
Sahu DK; Singh N; Das M; Rawat J; Gupta DK
Pediatr Surg Int; 2022 Nov; 38(11):1601-1617. PubMed ID: 36107237
[TBL] [Abstract] [Full Text] [Related]
7. Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.
Shiraishi Y; Kishimoto J; Shimose T; Toi Y; Sugawara S; Okamoto I
BMC Cancer; 2022 Sep; 22(1):964. PubMed ID: 36076179
[TBL] [Abstract] [Full Text] [Related]
8. Novel Therapeutics for Advanced Differentiated Thyroid Cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract] [Full Text] [Related]
9. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
[TBL] [Abstract] [Full Text] [Related]
10. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of Cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
11. ret receptor signaling: Function in development, metabolic disease, and cancer.
Takahashi M
Proc Jpn Acad Ser B Phys Biol Sci; 2022; 98(3):112-125. PubMed ID: 35283407
[TBL] [Abstract] [Full Text] [Related]
12. Mesenchymal neoplasms with NTRK and other kinase gene alterations.
Davis JL; Al-Ibraheemi A; Rudzinski ER; Surrey LF
Histopathology; 2022 Jan; 80(1):4-18. PubMed ID: 34958503
[TBL] [Abstract] [Full Text] [Related]
13. ALK rearrangements in infantile fibrosarcoma-like spindle cell tumours of soft tissue and kidney.
Tan SY; Al-Ibraheemi A; Ahrens WA; Oesterheld JE; Fanburg-Smith JC; Liu YJ; Spunt SL; Rudzinski ER; Coffin C; Davis JL
Histopathology; 2022 Mar; 80(4):698-707. PubMed ID: 34843129
[TBL] [Abstract] [Full Text] [Related]
14. OLFM4-ret fusion is an oncogenic driver in small intestine adenocarcinoma.
Liu W; Li H; Aerbajinai W; Botos I; Rodgers GP
Oncogene; 2022 Jan; 41(1):72-82. PubMed ID: 34675408
[TBL] [Abstract] [Full Text] [Related]
15. Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence.
Santoni M; Iacovelli R; Colonna V; Klinz S; Mauri G; Nuti M
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1029-1054. PubMed ID: 34445927
[TBL] [Abstract] [Full Text] [Related]
16. Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma.
Penning AJ; Al-Ibraheemi A; Michal M; Larsen BT; Cho SJ; Lockwood CM; Paulson VA; Liu YJ; Plank L; Fritchie K; Beadling C; Neff TL; Corless CL; Rudzinski ER; Davis JL
Mod Pathol; 2021 Aug; 34(8):1530-1540. PubMed ID: 33850302
[TBL] [Abstract] [Full Text] [Related]
17. Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma.
Bratslavsky G; Gleicher S; Jacob JM; Sanford TH; Shapiro O; Bourboulia D; Gay LM; Andrea Elvin J; Vergilio JA; Suh J; Ramkissoon S; Severson EA; Killian JK; Schrock AB; Chung JH; Miller VA; Mollapour M; Ross JS
Urol Oncol; 2021 Jun; 39(6):367.e1-367.e5. PubMed ID: 33775530
[TBL] [Abstract] [Full Text] [Related]
18. Intracellular ret signaling pathways activated by GDNF.
Kawai K; Takahashi M
Cell Tissue Res; 2020 Oct; 382(1):113-123. PubMed ID: 32816064
[TBL] [Abstract] [Full Text] [Related]
19. CHEK2 Mutation in Patient with Multiple Endocrine Glands tumors. Case Report.
Szeliga A; Pralat A; Witczak W; Podfigurna A; Wojtyla C; Kostrzak A; Meczekalski B
Int J Environ Res Public Health; 2020 Jun; 17(12):. PubMed ID: 32570972
[TBL] [Abstract] [Full Text] [Related]
20. A phase I study investigation of metabolism, and disposition of [
Liu Y; Liu L; Liu L; Wang T; Guo L; Wang Y; Gao Z; Shu Y
Cancer Chemother Pharmacol; 2020 May; 85(5):907-915. PubMed ID: 32266457
[TBL] [Abstract] [Full Text] [Related]
[Next]
